Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 59
- Registration Number
- NCT03554083
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Centre Antoine Lacassagne
- Target Recruit Count
- 103
- Registration Number
- NCT03548428
- Locations
- 🇫🇷
Centre Georges François LECLERC, Dijon, France
🇫🇷Centre Oscar LAMBRET, Lille, France
🇫🇷Centre François BACLESSE, Caen, France
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 212
- Registration Number
- NCT03540420
- Locations
- 🇳🇴
Universitetssykehuset Nord-Norge, Tromsø, Norway
🇸🇪Sahlgrenska Universitetssjukhus, Göteborg, Sweden
🇳🇴Sørlandet Sykehus, Kristiansand, Norway
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 211
- Registration Number
- NCT03533283
- Locations
- 🇧🇪
UZ Gent, Gent, Belgium
🇺🇸Novant Health Cancer Institute, Charlotte, North Carolina, United States
🇩🇰Rigshospitalet; Hæmatologisk Klinik, Klinisk Afprøvnings Team KAT, København Ø, Denmark
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 40
- Registration Number
- NCT03526900
- Locations
- 🇪🇸
Hospital Universitari Germans Tries i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 110
- Registration Number
- NCT03526432
- Locations
- 🇺🇸
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸UAB Women and Infants Center, Birmingham, Alabama, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
- Conditions
- Advanced Bladder Urothelial CarcinomaAdvanced Ureter Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Renal Pelvis Urothelial CarcinomaMetastatic Urothelial CarcinomaRecurrent Urethral Urothelial CarcinomaStage III Urethral Cancer AJCC v8Unresectable Bladder Urothelial CarcinomaRecurrent Bladder Urothelial CarcinomaStage IVA Bladder Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-05-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT03513952
- Locations
- 🇺🇸
FHCC South Lake Union, Seattle, Washington, United States
🇺🇸University of Hawaii Cancer Center, Honolulu, Hawaii, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Inovio Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT03502785
- Locations
- 🇺🇸
Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2199
- Registration Number
- NCT03498716
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇦🇺Royal Adelaide Hospital; Cancer Centre, Adelaide, South Australia, Australia
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
- Conditions
- Interventions
- Drug: AlectinibDrug: VismodegibDrug: IpatasertibDrug: CarboplatinDrug: OlaparibDrug: ErlotinibDrug: CisplatinDrug: BevacizumabDrug: GemcitabineDrug: VemurafenibDrug: CobimetinibDrug: Trastuzumab Subcutaneous (SC)Drug: PertuzumabDrug: AtezolizumabDrug: PaclitaxelDrug: EntrectinibDrug: IvosidenibDrug: Pemigatinib
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 528
- Registration Number
- NCT03498521
- Locations
- 🇦🇺
Northern Cancer Institute, St Leonards, New South Wales, Australia
🇦🇺Blacktown Hospital, Blacktown, New South Wales, Australia
🇫🇮Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.